Free Trial

CEL-SCI (CVM) Competitors

CEL-SCI logo
$2.29 -0.20 (-8.03%)
Closing price 04:00 PM Eastern
Extended Trading
$2.33 +0.04 (+1.79%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVM vs. COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, LSTA, CYTH, and FBLG

Should you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), Cyclo Therapeutics (CYTH), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical products" industry.

CEL-SCI vs. Its Competitors

Coeptis Therapeutics (NASDAQ:COEP) and CEL-SCI (NYSE:CVM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 9.9% of CEL-SCI shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Coeptis Therapeutics has a beta of -0.63, meaning that its stock price is 163% less volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

CEL-SCI's return on equity of -238.05% beat Coeptis Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Coeptis TherapeuticsN/A -282.39% -127.23%
CEL-SCI N/A -238.05%-104.65%

Coeptis Therapeutics is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-1.33
CEL-SCIN/AN/A-$26.92M-$12.61-0.18

In the previous week, Coeptis Therapeutics' average media sentiment score of 0.00 equaled CEL-SCI'saverage media sentiment score.

Company Overall Sentiment
Coeptis Therapeutics Neutral
CEL-SCI Neutral

Summary

Coeptis Therapeutics beats CEL-SCI on 5 of the 8 factors compared between the two stocks.

Get CEL-SCI News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CVM vs. The Competition

MetricCEL-SCIBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$6.94M$205.72M$5.45B$20.45B
Dividend YieldN/AN/A5.22%3.72%
P/E Ratio-4.77N/A27.2427.83
Price / SalesN/A242.79426.1546.02
Price / CashN/A22.4426.2118.22
Price / Book15.275.557.924.59
Net Income-$26.92M-$96.61M$3.17B$982.91M
7 Day PerformanceN/A-1.69%4.40%1.73%
1 Month Performance-3.78%-2.54%2.64%4.26%
1 Year Performance-93.69%11.05%35.04%14.35%

CEL-SCI Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CVM
CEL-SCI
0.0764 of 5 stars
$2.29
-8.0%
N/A-93.1%$6.94MN/A-4.7743High Trading Volume
COEP
Coeptis Therapeutics
0.1953 of 5 stars
$7.80
+0.3%
N/A+35.6%$27.34MN/A-1.342
SXTC
China SXT Pharmaceuticals
0.1436 of 5 stars
$1.73
+0.6%
N/A-78.1%$27.22M$1.93M0.0090Gap Down
SCYX
SCYNEXIS
0.2625 of 5 stars
$0.67
-2.4%
N/A-60.9%$26.98M$3.75M-1.2060
NRSN
NeuroSense Therapeutics
1.6855 of 5 stars
$1.89
-0.5%
$14.00
+640.7%
+55.3%$25.97MN/A-3.5010Gap Down
TPST
Tempest Therapeutics
1.6221 of 5 stars
$6.80
-1.4%
$30.00
+341.2%
-72.8%$25.41MN/A-0.3820
CARA
Cara Therapeutics
0.3381 of 5 stars
N/AN/AN/A$24.33M$7.14M-0.2580Gap Down
High Trading Volume
TENX
Tenax Therapeutics
1.2486 of 5 stars
$5.76
-1.5%
$17.50
+203.8%
+88.0%$24.27MN/A-2.329
LSTA
Lisata Therapeutics
2.4741 of 5 stars
$2.90
+3.6%
$15.00
+417.2%
-24.8%$24.12M$1M-1.2630Positive News
CYTH
Cyclo Therapeutics
N/A$0.72
flat
$0.95
+31.8%
N/A$23.72M$870.73K-0.809
FBLG
FibroBiologics
2.522 of 5 stars
$0.62
+0.7%
$13.00
+1,989.4%
-87.0%$23.65MN/A-2.9610News Coverage
Gap Up

Related Companies and Tools


This page (NYSE:CVM) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners